Organogenesis Holdings Inc ORGO.OQ ORGO.O is expected to show a rise in quarterly revenue when it reports results on November 12 for the period ending September 30 2024
The Canton Massachusetts-based company is expected to report a 0.3% increase in revenue to $108.833 million from $108.53 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.The company's guidance on August 8 2024, for the period ended September 30, was for revenue between $105.00 million and $113.00 million.
LSEG's mean analyst estimate for Organogenesis Holdings Inc is for a loss of 1 cent per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The average consensus recommendation for the biotechnology & medical research peer group is also "Buy".
Wall Street's median 12-month price target for Organogenesis Holdings Inc is $4.25, above its last closing price of $3.26.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | 0.00 | 0.00 | 0.04 | Beat | |
Mar. 31 2024 | -0.03 | -0.03 | -0.02 | Beat | 25 |
Dec. 31 2023 | 0.01 | 0.01 | 0.00 | Missed | -100 |
Sep. 30 2023 | 0.00 | 0.01 | 0.02 | Beat | 300 |
Jun. 30 2023 | 0.02 | 0.03 | 0.04 | Beat | 60 |
Mar. 31 2023 | -0.02 | -0.02 | -0.02 | Met | 0 |
Dec. 31 2022 | 0.05 | 0.05 | 0.06 | Beat | 20 |
Sep. 30 2022 | 0.06 | 0.06 | 0.00 | Missed | -100 |
This summary was machine generated November 8 at 21:55 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.